PFM Health Sciences’s BioMarin Pharmaceuticals BMRN Stock Holding History

PFM Health Sciences’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-213,100	Closed	-$18.9M	–	67
2023 Q3	$18.9M	Buy	+213,100	New	+$19M	0.89%	41
2023 Q1	–	Sell	-243,000	Closed	-$25.1M	–	85
2022 Q4	$25.1M	Buy	243,000 +63,000	+35%	+$5.91M	0.9%	44
2022 Q3	$15.3M	Buy	+180,000	New	+$16M	0.55%	57
2021 Q1	–	Sell	-371,700	Closed	-$32.6M	–	91
2020 Q4	$32.6M	Buy	371,700 +85,500	+30%	+$6.78M	1.15%	34
2020 Q3	$21.8M	Buy	+286,200	New	+$29M	1.01%	39

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PFM Health Sciences's BMRN Position: Q3 2025 in Review

PFM Health Sciences sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 178,319 shares — an estimated $9.8M sold.

PFM Health Sciences first reported a position in BMRN in Q2 2016 and held it in 21 quarters. The position peaked at $178M in Q2 2019. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

PFM Health Sciences reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
PFM Health Sciences sold 178,319 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $9.8M.
PFM Health Sciences first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 21 quarters.
PFM Health Sciences's BioMarin Pharmaceuticals position peaked at $178M in Q2 2019.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.